-
【Conference Summary】2022 International Conference on Thrombosis and Hemostasis (ISTH) Cutting-edge Information Sharing
Time of Update: 2022-10-14
The second session is to keep the clouds open to see the moon - progress in the field of pediatrics of hemophilia Professor Wu Runhui of Beijing Children's Hospital affiliated to Capital Medical University shared a number of academic achievements around "Exploration of Treatment Strategies for Children with Hemophilia in China", including 9 abstracts, 1 oral communication and RPTH Editing Award.
-
2022CSH Prof. Yu Hu: Review and future prospects of hemophilia in the past 40 years
Time of Update: 2022-10-14
Hemohilia is an X-linked, recessive bleeding disorder caused by a deficiency of factor VIII or factor IX, which is related to the corresponding coagulation factor gene mutation. In recent years, new d
-
2022CSH Professor Song Yongping: The development of auto-HSCT needs attention, and the appropriate pre-transplant treatment scheme is crucial to improving the cure rate and safety of HSCT!
Time of Update: 2022-10-14
On this occasion, Yimaitong specially invited Professor Song Yongping of the First Affiliated Hospital of Zhengzhou University to be interviewed to share the application status and development prospects of hematopoietic stem cell transplantation (HSCT) in blood diseases combined with clinical experience, as well as the development status of HSCT pretreatment program.
-
Reconstructing the hope, Mövenpick Renaissance | Professor Shi Yuankai: the research and development status and challenges of domestic innovative drugs in the field of lymphoma and the listing prospect of repatitumab (Anpingxi ®).
Time of Update: 2022-10-14
In recent years, with the continuous emergence of new drugs, lymphoma treatment plans have been continuously updated, and the overall survival of lymphoma patients has been continuously improved. Beca
-
2022CSH Transmission Transplantation Progress, Interpretation of Academic Frontiers, the 17th National Hematology Academic Conference of the Chinese Medical Association - Hematopoietic Stem Cell Transplantation Group Forum was successfully concluded
Time of Update: 2022-10-14
Listen to the sound of blood and feel the rhythm of life. The 17th National Hematology Academic Conference of the Chinese Medical Association, sponsored by the Chinese Medical Association and the Hema
-
ESMO interviews Professor Cen Hong: PD-1 gene knockdown targeted CD19 CAR-T cell therapy relapsed refractory B cell lymphoma prospect may be expected
Time of Update: 2022-10-14
Professor Cen Hong: This study is a single-arm, Phase I study that explores the initial efficacy and safety of PD-1 gene knockdown targeted CD19 CAR-T cells, and enrolled 16 patients, 12 patients with recurrent refractory B-cell lymphoma (8 cases of diffuse large B-cell lymphoma [DLBCL], 2 cases of follicular lymphoma [FL], 1 case of chronic lymphocytic leukemia [CLL], and 1 case of high-grade B-cell lymphoma [HGBL]).
-
The results of the 6-year follow-up of the RELEVANCE study are announced! Can R2 surpass R-chemo in patients with follicular lymphoma?
Time of Update: 2022-10-14
Results of the study Baseline characteristics From December 2011 to November 2014, a total of 1030 patients were randomly assigned 1:1 to receiveR2 (n=513) or R-chemo (n=517), respectively, with similar baseline characteristics in both groups (Table 1).
-
CSH Innovation Forum| Lv Ben, Du Xin, Wu Wen, Wang Zhao, Li Fei and Hu Xiaoxia invite you to join the academic feast on September 23-25 - the 17th National Conference on Hematology of the Chinese Medical Association
Time of Update: 2022-10-14
Professor Wu Wen Ruijin Hospital, Shanghai Jiao Tong University School of Medicine The National Hematology Academic Conference set up a bone marrow proliferative disease forum for the first time, inviting top scholars at home and abroad in the field of bone marrow proliferative diseases to report on the latest progress in clinical research and basic research of bone marrow proliferative diseases, and will also introduce the project of the Standardized Diagnosis and Treatment Demonstration Center for Myeloproliferative Diseases.
-
Improve the survival prognosis and improve the quality of life, CD38 monoclonal antibody helps to break the dilemma of MM treatment for the elderly
Time of Update: 2022-10-14
8Figure 6 BOSTON studies PFS and OS trends in each subgroupElderly patients with frail MM have a poor prognosis and need to develop or optimize more effective frailty assessment tools to accurately identify and treat them on the premise that toxic side effects are tolerated.
-
2022 SOHO Quizartinib Research Advances in Newly Diagnosed AML Patients: QuANTUM-First Phase III Study Results
Time of Update: 2022-10-14
The QuANTUM-First study (NCT02668653) is a global, randomized, double-blind, phase III study evaluating the efficacy of Quizartinib monotherapy (up to 3 years) after standard induction and post-remission consolidation therapy in patients with newly diagnosed FLT3-ITD+ AML.
-
Roundtable pie to inventory the most common types of leukemia acute myeloid leukemia treatment, the efficacy of the improvement "future can be expected"
Time of Update: 2022-10-14
In recent years, with the application of new targeted drugs and biological therapies combined with traditional chemotherapy and hematopoietic stem cell transplantation, the efficacy of AML has improved significantly.
-
Professors Wu Depei and Zhang Xi: Concentric relay, continuing hope, innovative ADC drug Pola opens up a new pattern suitable for transplanted R/R DLBCL treatment
Time of Update: 2022-10-14
GuideEvery opening of the unknown world has the brave foresight of pioneers; Every journey of sneaking in the dark night, there is a little lamp man fearlessly leading the way. The series of reports "
-
2022CSH Professor Niu Ting: Based on the present, looking to the future, the development of multiple myeloma treatment in China
Time of Update: 2022-10-14
Listening to the sound of blood and perceiving the rhythm of life, the much-anticipated "17th National Hematology Academic Conference of the Chinese Medical Association" has been held on September 23-
-
International experts work together to discuss the future: the evolution of CLL treatment mode driven by MRD
Time of Update: 2022-10-14
With the development of medicine, at least half of patients can achieve complete remission (CR) after first-line standard therapy, and the clinical need for more sensitive comparison of the results of different protocols, MRD testing is of great significance.
-
CSH Innovation Forum| Jiang Qian, Liu Ligen, Xu Pengpeng, He Yang invite you to join the academic feast on September 23-25 - the 17th National Hematology Academic Conference of the Chinese Medical Association
Time of Update: 2022-10-14
R&D pipeline forum September 24 13:30-17:30 Professor Xu Pengpeng Ruijin Hospital, Shanghai Jiao Tong University School of Medicine Transforming new molecular targets in the laboratory into targeted drugs that can be used in clinical applications for the benefit of patients is the direction of the joint efforts of hematology colleagues and pharmaceutical companies.
-
CSH Innovation Forum| Dong Wenge, Wu Tao, Cuckoo, Chen Chong, Liu Yu, He Yang invite you to join the academic feast on September 23-25 - the 17th National Hematology Academic Conference of the Chinese Medical Association
Time of Update: 2022-10-14
Nursing session September 9 23:8-00:12 Heyang Nursing Supervisor Ruijin Hospital, Shanghai Jiao Tong University School of Medicine Hello experts and nursing colleagues, it is a great honor to hold the 17th National Hematology Academic Conference and Nursing Sub-forum of the Chinese Medical Association in Shanghai.
-
2022CSH focuses on the frontiers of transplantation and explores the way of diagnosis and treatment, and the 17th National Hematology Academic Conference of the Chinese Medical Association - Transplantation Frontier Forum is wonderful!
Time of Update: 2022-10-14
Under the co-chairmanship of Professor Wang Fengrong of Peking University People's Hospital and Professor Guo Mei of the Fifth Medical Center of the General Hospital of the People's Liberation Army of Chinese, Professor Sun Yuqian of Peking University People's Hospital deeply interpreted the "Expert Consensus on the Treatment of Blood System Diseases by Allogeneic Hematopoietic Stem Cell Transplantation in China (2021 Updated Edition)".
-
Can combination chemotherapy after targeted therapy improve the efficacy of the initial treatment of patients with non-GCB diffuse large B-cell lymphoma?
Time of Update: 2022-10-14
In addition, studies have shown good efficacy with rituximab, lenalidomide, and ibratinib (RLI) in patients with recurrent non-GCB DLBCL with a total response rate (ORR) of 65%, median progression-free survival (PFS) of 5.
-
2022CSH Professor Jianxiang Wang: The CD19 CAR-T Herkirun race is poised in r/r ALL
Time of Update: 2022-10-14
Adult acute lymphoblastic leukemia (ALL) is one of the most common acute leukemias in adults, accounting for about 20% to 30%. In recent years, the rapid development of chimeric antigen receptor T (CA
-
EFS24 is expected to be a prognostic factor for patients with initially treated mantle cell lymphoma
Time of Update: 2022-10-13
Figure 4 OS comparison and causes of death in patients who achieve EFS24 after immunochemotherapy with the general populationConclusion of the studySurvival outcomes have improved in patients with initial MCL in more recent time periods (cohort 2), which may be related to recent advances in first-line and salvage care for MCL.